September 25, 2025Pediatric Blood & CancerOpen Access

Post‐Transplant Cyclophosphamide for Graft‐Versus‐Host Disease Prophylaxis in Pediatric Stem Cell Transplantation

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Review reveals post-transplant cyclophosphamide improves GVHD outcomes in pediatric stem cell transplantation, highlighting its growing relevance.

Post-transplant cyclophosphamide reduces graft-versus-host disease incidence in pediatric patients, supporting its increased use.
Data shows that PTCy has demonstrated efficacy in both haploidentical and matched donor stem cell transplants, indicating broader application.
The review includes analysis of studies on PTCy in pediatric and adult settings, emphasizing the urgent need for more pediatric trials.
Continued promotion of PTCy for GVHD prophylaxis could lead to significant improvements in pediatric transplant outcomes, reducing mortality.

Fan et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Review reveals post-transplant cyclophosphamide improves GVHD outcomes in pediatric stem cell transplantation, highlighting its growing relevance.